877-272-6226
TACKLING THE WORLD’S TOUGHEST CANCER – TOGETHER
To fight the world’s toughest cancer, PanCAN has built the Community for Progress, a robust and collaborative research community to tackle the disease from all angles. These scientists, clinicians, patients, industry partners and visionary donors drive groundbreaking scientific and clinical initiatives to improve outcomes for all patients with pancreatic cancer.
This year, we are excited to bring the PanCAN Community for Progress together in person for PanCAN Scientific Summit 2022, where you will have the opportunity to:
- Meet our new PanCAN research grant recipients
- Learn more about our top research initiatives
- Hear from PanCAN’s young investigators as well as senior research grant recipients
- Engage in discussions about emerging science in the field
- Meet colleagues, collaborators, patient research advocates, and some rising stars in the field
When the Summit ends, we hope you stay in Boston to attend the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer. PanCAN is proud to be a major sponsor of this conference and we hope to see you there after the Summit concludes.
PanCAN has a bold goal to drive the 5-year survival rate of pancreatic cancer to 20% by 2030. We can’t do it without you! Thank you for joining us as we keep pancreatic cancer research moving forward, together.
*Attire: Business / Business Casual / Wear Your Purple!
Monday, September 12, 2022
5:30 p.m. — 6:30 p.m.
PanCAN Scientific and Medical Advisory Board Reception (closed, invite only)
6:30 p.m. — 10:00 p.m.
General Reception
Welcome Remarks
Julie Fleshman, JD, MBA, PanCAN President and CEO
Poster Session
2021 Class of Career Development Awards and Fellowships
Evaluation of Antitumor Immunity in Human Clinical Trials
Victoire Cardot-Ruffino, PhD, Dana-Farber Cancer Institute
Grant Funded by The Francois Wallace Monahan Fund in memory of Michael Insel
Preclinical Evaluation of Netrin-1 Antibody for Treatment of Pancreatic Cancer
Charline Ogier, PhD, Fox Chase Cancer Center
Grant funded by The Francois Wallace Monahan Fund in memory of Michael Insel
Hnf1b Defines an Epigenetic Ontology of Human Pancreatic Cancer
Rohit Chandwani, MD, PhD, Weill Cornell Medicine
Grant funded by The Jim & Shirley Young Family Foundation
Metabolic Link to Immunosuppressive Fibroblasts in Pancreatic Cancer
Ralph Francescone, PhD, Fox Chase Cancer Center
Grant funded in memory of Skip Viragh
Targeting BARD1 in Pancreatic Ductal Adenocarcinoma
Aditi Jain, PhD, Thomas Jefferson University
Dissecting Malignant Evolution Unleashed by p53 Inactivation in PDAC
John Morris IV, PhD, University of North Carolina at Chapel Hill
Grant funded in memory of Skip Viragh
Developing Engineered Proteins to Enhance Adoptive Cell Therapy of PDA
Shannon Oda, PhD, Seattle Children’s Research Institute
Grant funded by Linda E. Amuso in memory of Susan A. Lombardi
Fibrosis-mediated Transformation in Pancreatic Cancer Risk Factors In Vitro
Catherine Whittington, PhD, Worcester Polytechnic Institute
Tuesday, September 13, 2022
8:00 a.m. — 8:30 a.m.
Breakfast
8:30 a.m. — 8:35 a.m.
Community for Progress and 2022 Scientific Summit Overview
Margaret Tempero, MD, University of California, San Francisco Chair, PanCAN Scientific and Medical Advisory Board
8:35 a.m. — 8:55 a.m.
PanCAN State of the Union and Welcome 2022 Class of Grantees
Julie Fleshman, JD, MBA
8:55 a.m. — 9:50 a.m.
Early Detection
Session Facilitator: Lynn Matrisian, PhD, MBA, PanCAN Chief Science Officer
8:55 a.m. — 9:20 a.m.
PanCAN Early Detection Initiative
Suresh Chari, MD, MD Anderson Cancer Center Study PI
9:20 a.m. — 9:50 a.m.
Early Detection Research Project
Racial/ethnic Equity in GENetic Education, Risk Assessment and Testing (REGENERATE) Study
Sapna Syngal, MD, MPH, Dana-Farber Cancer Institute
Grant extension funded by Janssen Research & Development, LLC
Nicolette Juliana Rodriguez, MD, MPH, Brigham and Women’s Hospital
Grant funded by an anonymous donor
9:50 a.m. — 10:00 a.m.
Break
10:00 a.m. — 11:40 a.m.
Career Development Awards
10:00 a.m. — 10:20 a.m.
Microenvironment Induced Metabolic Requirements of Pancreatic Cancers
Alexander Muir, PhD, University of Chicago
10:20 a.m. — 10:40 a.m.
Duodenal Control of Pancreatic Ductal Adenocarcinoma
Daria Esterházy, PhD, University of Chicago
10:40 a.m. — 11:00 a.m.
CA 19-9 Promotes Pancreatitis and Pancreatic Cancer
Jan Lumibao, PhD, Salk Institute for Biological Studies (on behalf of Dannielle Engle, PhD)
Grant funded in memory of Skip Viragh
11:00 a.m. — 11:20 a.m.
Delineating Oncogenic Circuitries of GNAS Mutant Pancreatic Neoplasms
Krushna Patra, PhD, University of Cincinnati
Grant funded by Steven & Cheryl Kole and Harriet & Gerald Berner Family Charitable Fund
11:20 a.m. — 11:40 a.m.
Targeting Transcription-Replication Conflicts in Pancreatic Cancer
Mustafa Raoof, MD, FACS, Beckman Research Institute of the City of Hope
Grant funded in memory of Skip Viragh
11:40 a.m. — 12:00 p.m.
Research Acceleration Network Grant
Eliminating T Cell Barriers in Pancreatic Cancer Patients
Steven Leach, MD, Dartmouth College
Grant funded by Celgene Corporation
12:00 p.m. — 12:50 p.m.
Lunch
12:50 p.m. — 1:00 p.m.
Industry Member Interlude
1:00 p.m. — 2:00 p.m.
Translational Research Grants
1:00 p.m. — 1:20 p.m.
Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer
Kenneth Olive, PhD, Columbia University
1:20 p.m. — 1:40 p.m.
Proglumide and the Pancreatic Cancer Microenvironment
Jill Smith, MD, Georgetown University
1:40 p.m. — 2:00 p.m.
Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer
Darren Carpizo, MD, PhD, University of Rochester
2:00 p.m. — 2:10 p.m.
PanCAN SPARK Health Data Platform
Sudheer Doss, PhD, PanCAN Chief Business Officer
Kawther Abdilleh, PhD, PanCAN Associate Director, Health Data Analytics
2:10 p.m. — 2:50 p.m.
PanCAN Precision Promise
Session Facilitator: Diane Simeone, MD, NYU Langone Health Chair, Precision Promise Steering Committee
2:10 p.m. — 2:15 p.m.
Precision PromiseSM Update
Diane Simeone, MD
2:15 p.m. — 2:35 p.m.
Precision Promise Correlative Study
IL-1b in pancreatic cancer induces local and systemic immunosuppression: correlates from the Precision Promise safety run-in trial of canakinumab, spartalizumab, and gemcitabine/n(ab) paclitaxel
Stephanie Dougan, PhD, Dana-Farber Cancer Institute
2:35 p.m. — 2:55 p.m.
Precision Medicine Targeted Grant
Murine Clinical Trials for the Evaluation of High Priority Therapeutic Targets for Precision Promise
Sunil Hingorani, MD, PhD, University of Nebraska
Grant Extensions funded by 1440 foundation; Cheryl & Steve Kole, and Rudy Revak
2:55 p.m. — 3:15 p.m.
Therapeutic Accelerator Award
Phase 1/2 Trial of VS-6766 + Defactinib and GEM + Nab-P in metastatic PDAC
Louis Denis, MD, and Jonathan Pachter, PhD, Verastem Oncology, Inc.
Grant supported by the 1440 Foundation and the Gail V. Coleman-Kenneth M. Bruntel Research Fund
3:15 p.m. — 3:30 p.m.
Closing Remarks
Margaret Tempero, MD
Julie Fleshman, JD, MBA
Suresh Chari, MD
MD Anderson Cancer Center
Affiliation: Early Detection Initiative, Study PI
Topic: Early Detection Initiative (EDI Update)
Sapna Syngal, MD, MPH
Dana-Farber Cancer Institute
Grant: 2021 Pancreatic Cancer Action Network Research Project, 2022 Pancreatic Cancer Action Network Catalyst Award funded by Janssen Research & Development, LLC
Topic: Racial/ethnic Equity in Genetic Education, Risk Assessment and Testing (REGENERATE) Study
Nicolette Juliana Rodriguez, MD, MPH
Brigham and Women’s Hospital
Grant: 2022 Pancreatic Cancer Action Network Catalyst Award Funded by an Anonymous Donor
Topic: Racial/ethnic Equity in Genetic Education, Risk Assessment and Testing (REGENERATE) Study
Alexander Muir, PhD
University of Chicago
Grant: 2020 Pancreatic Cancer Action Network Career Development Award
Topic: “Microenvironment Induced Metabolic Requirements of Pancreatic Cancers”
Daria Esterháazy, PhD
University of Chicago
Grant: 2020 Pancreatic Cancer Action Network Career Development Award
Topic: Duodenal Control of Pancreatic Ductal Adenocarcinoma
Jan Lumibao, PhD (on behalf of Dannielle Engle, PhD)
Salk Institute for Biological Studies
Grant: 2019 Skip Viragh Pancreatic Cancer Action Network Career Development Award
Topic: CA 19-9 Promotes Pancreatitis and Pancreatic Cancer
Krushna Patra, PhD
University of Cincinnati
Grant: 2020 Pancreatic Cancer Action Network Career Development Award, funded by Steven & Cheryl Kole and Harriet & Gerald Berner Family Charitable Fund
Topic: Delineating Oncogenic Circuitries of GNAS Mutant Pancreatic Neoplasms
Mustafa Raoof, MD, FACS
Beckman Research Institute of the City of Hope
Grant: 2020 Pancreatic Cancer Action Network Career Development Award in memory of Skip Viragh
Topic: Targeting Transcription-Replication Conflicts in Pancreatic Cancer
Steven Leach, MD
Dartmouth College
Grant: 2015 Celgene Corporation – Pancreatic Cancer Action Network – AACR Research Acceleration Network Grant
Topic: Eliminating T cell barriers in pancreatic cancer patientsr
Kenneth Olive, PhD
Columbia University
Grant: 2020 Pancreatic Cancer Action Network Translational Research Grant
Topic: Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer
Jill Smith, MD
Georgetown University
Grant: 2020 Pancreatic Cancer Action Network Translational Research Grant
Topic: Proglumide and the Pancreatic Cancer Microenvironment
Darren Carpizo, MD, PhD
University of Rochester
Grant: 2018 Pancreatic Cancer Action Network Translational Research Grant
Topic: Investigating Netrin-1 as a New Therapeutic Target in Pancreatic Cancer
Diane Simeone
MD, NYU Langone Health
Affiliation: Chair, Precision Promise Steering Committee
Topic: Precision PromiseSM Update
Stephanie Dougan, PhD
Dana-Farber Cancer Institute
Topic: Precision Promise Correlative Study
Sunil Hingorani, MD, PhD
University of Nebraska
Grant: 2017 Pancreatic Cancer Action Network Precision Medicine Targeted Grant 2021 Extension funded by Cheryl and Steve Kole, and Rudy Revak
Topic: Murine Clinical Trials for the Evaluation of High Priority Therapeutic Targets for Precision Promise
Jonathan Pachter, PhD
Verastem Oncology
Grant: 2022 Pancreatic Cancer Action Network Therapeutic Accelerator Award supported by the 1440 Foundation, and the Gail V. Coleman-Kenneth M. Bruntel Research Fund
Topic: Phase 1/2 Trial of VS-6766 + Defactinib and GEM + Nab-P in metastatic PDAC
Louis Denis, MD
Verastem Oncology
Grant: 2022 Pancreatic Cancer Action Network Therapeutic Accelerator Award supported by the 1440 Foundation, and the Gail V. Coleman-Kenneth M. Bruntel Research Fund
Topic: Phase 1/2 Trial of VS-6766 + Defactinib and GEM + Nab-P in metastatic PDAC
More details to follow
THANK YOU
We're looking forward to seeing you at PanCAN Scientific Summit 2022 on September 12 & 13 in Boston, MA
